Immunotherapy does not impair ovarian function in a mouse model of breast cancer

• by Payton De La Cruz, Morgan F. Woodman-Sousa, Julia N. McAdams, Ellia Sweeney, Lola Hakim, Melanie Morales Aquino, Kathryn J. Grive

• July 2, 2026

ASCO26: Sara Tolaney, MD, MPH, ASCENT-03

Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.

• July 1, 2026

• 1 min

Crucial role of IL-6, IL-8, IL-11 and leptin in tumor microenvironment in a group of patients with GEP-NETs- crosstalk between inflammation and cancer

• by Agata Świętek, Joanna K. Strzelczyk, Dorota Hudy, Zenon P. Czuba, Karolina Snopek-Miśta, Mariusz Kryj, Katarzyna Kuśnierz, Marcin Zeman, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Janusz Strzelczyk

• July 2, 2026

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma

• by Luisina María Solernó, Candela Llavona, Zahira Yasmine Saud, Mariana Carolina Onassis, María Florencia Gottardo, Martín Manuel Ledesma, Daniel Fernando Alonso, Juan Garona

• July 1, 2026